The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

GFAP Astrocytopathy — Autoimmune Meningoencephalomyelitis

Autoimmune neurological disorder caused by autoantibodies targeting glial fibrillary acidic protein (GFAP) on astrocytes, characterized by meningoencephalomyelitis with characteristic perivascular radial enhancement on MRI and excellent corticosteroid response.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Nöroloji department. Book Appointment →

What is GFAP Astrocytopathy — Autoimmune Meningoencephalomyelitis?

Autoimmune GFAP astrocytopathy is a corticosteroid-responsive inflammatory CNS disease first described by Fang and Pittock in 2016, defined by detection of anti-GFAP-IgG antibodies in cerebrospinal fluid using cell-based assay against GFAP-alpha isoform.

Pathogenic mechanism involves T-cell mediated targeting of GFAP-expressing astrocytes; histology shows perivascular T-cell infiltrate, astrocyte loss, and reactive gliosis with relative neuronal preservation, distinguishing it from neuromyelitis optica spectrum disorders.

Tumor association is found in 20–30% of cases (ovarian teratoma, lung adenocarcinoma, melanoma, others), so cancer screening is essential at diagnosis; up to 30% of patients have coexisting NMDAR or AQP4 antibodies, suggesting immunological overlap.

Symptoms

Subacute meningoencephalitis with headache, fever, neck stiffness, and altered mental status
Movement disorders including tremor, ataxia, myoclonus, parkinsonism (atypical features)
Bilateral or unilateral optic disc edema with normal visual acuity, often distinct from typical optic neuritis
Myelopathy with sensory level, weakness, urinary retention
Seizures, psychiatric symptoms, autonomic dysfunction (orthostasis, dysautonomia)
Cognitive impairment, dementia-like presentation, particularly in subacute course

Risk Factors

Underlying neoplasm, particularly ovarian teratoma in young women, lung adenocarcinoma in older men
Coexisting autoimmune disease (Hashimoto, lupus, rheumatoid arthritis)
Other coexisting neural antibodies (AQP4, NMDAR) suggesting overlap syndromes
No clear genetic predisposition; HLA associations under investigation
Median age 40–50 years, slight female predominance
Earlier diagnosis and treatment correlate with better outcomes

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Subacute encephalitis or meningoencephalomyelitis without identified infectious cause — urgent neurology evaluation with CSF anti-GFAP testing
  • Atypical optic neuritis with disc edema and preserved acuity — neurology and neuro-ophthalmology
  • Movement disorder with concomitant cognitive or behavioral changes — autoimmune encephalitis workup
  • Suspected GFAP astrocytopathy with new vision change, weakness, or seizure — emergency MRI and immunotherapy initiation
  • Newly diagnosed GFAP astrocytopathy — comprehensive cancer screening with body PET-CT, gynecologic examination, age-appropriate screening

Treatment Methods

01
First-line: IV methylprednisolone 1 g/day for 5 days followed by oral prednisone taper over 6–12 months; most patients respond within days to weeks
02
Combine with intravenous immunoglobulin (IVIG) 2 g/kg over 5 days or plasma exchange in severe or refractory cases
03
Maintenance immunotherapy with mycophenolate mofetil, azathioprine, or rituximab in patients with relapse or steroid-dependent disease
04
Tumor screening at diagnosis (PET-CT body, age-appropriate cancer screening) and again 3–6 months later if initially negative; remove tumor if found, which often improves neurological course
05
Long-term follow-up with brain MRI, CSF testing for relapse, monitoring for immunotherapy side effects, and ongoing tumor surveillance especially with classical paraneoplastic associations

Which Department to Visit?

You can visit our Nöroloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Nöroloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Headache and Migraine

Nöroloji

What you need to know about headache types, migraine attacks, and triggering factors.

Low Back Pain

Nöroloji

Learn about the most common causes of low back pain, risk factors, and appropriate treatment approaches.

Neck Pain and Cervical Disc Herniation

Nöroloji

Learn about the symptoms and treatment options for cervical disc herniation and problems in the neck region.

Epilepsy

Nöroloji

Accurate information about epilepsy, types of seizures, and recommendations for patients and families.

Parkinson Disease

Nöroloji

Parkinson disease is caused by progressive degeneration of dopaminergic neurons and alpha-synuclein accumulation; well-timed therapy substantially improves function and quality of life.

Alzheimer's Disease and Dementia

Nöroloji

Information about early signs, diagnosis, and the care process for Alzheimer's and other types of dementia.

Multiple Sclerosis (MS)

Nöroloji

What is multiple sclerosis, who is at risk, and which treatments are applied?

Stroke

Nöroloji

What is stroke, what are the FAST signs, and why is emergency intervention critical?

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.